A detailed history of Twinbeech Capital LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Twinbeech Capital LP holds 253,795 shares of ACAD stock, worth $4.33 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
253,795
Holding current value
$4.33 Million
% of portfolio
0.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.14 - $19.14 $3.84 Million - $4.86 Million
253,795 New
253,795 $3.91 Million
Q1 2024

May 15, 2024

BUY
$17.79 - $30.86 $2.54 Million - $4.4 Million
142,496 New
142,496 $2.63 Million
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $2.52 Million - $4.05 Million
121,058 Added 61.92%
316,555 $6.6 Million
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $1.42 Million - $2.05 Million
79,798 Added 68.97%
195,497 $4.68 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $1.89 Million - $2.42 Million
115,699 New
115,699 $2.18 Million
Q2 2022

Aug 15, 2022

BUY
$13.01 - $27.22 $1.04 Million - $2.17 Million
79,579 New
79,579 $1.12 Million
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $447,404 - $587,565
-21,366 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $358,735 - $578,804
21,366 New
21,366 $499,000
Q2 2021

Aug 16, 2021

SELL
$19.4 - $27.42 $581,515 - $821,914
-29,975 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $649,043 - $1.43 Million
25,941 Added 643.06%
29,975 $773,000
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $584,943 - $809,427
-14,253 Reduced 77.94%
4,034 $216,000
Q3 2020

Nov 16, 2020

BUY
$36.42 - $57.0 $666,012 - $1.04 Million
18,287 New
18,287 $754,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.